Treatment of metastatic colorectal cancer with cetuximab: Influence on the quality of life

Zeitschrift fur Gastroenterologie

Volumn 51, Issue 8, 2013, Pages 733-739

  Unger, K ^a   Niehammer, U ^a   Hahn, A ^a   Goerdt, S ^a   Schumann, M ^a   Thum, S ^a   Schepp, W ^a  

^a KLINIKUM BOGENHAUSEN   (Germany)

Author keywords

colorectal cancer; Epidermal Growth Factor Receptor Inhibitor; palliative treatment; psycho oncology; quality of life; skin toxicities

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB;

ADULT; ARTICLE; BECK DEPRESSION INVENTORY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; COGNITIVE DEFECT; COPING BEHAVIOR; DEMOGRAPHY; DEPRESSION; FEMALE; HEALTH BELIEF; HUMAN; LOCUS OF CONTROL; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; METASTATIC COLORECTAL CANCER; NEUROSIS; OUTPATIENT; POST HOC ANALYSIS; PSYCHOLOGIC ASSESSMENT; QUALITY OF LIFE; QUESTIONNAIRE; SKIN MANIFESTATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; COMORBIDITY; DRUG ERUPTIONS; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; PREVALENCE; QUALITY OF LIFE; RISK FACTORS; TREATMENT OUTCOME;

EID: 84882790613     PISSN: 00442771     EISSN: 14397803     Source Type: Journal    
DOI: 10.1055/s-0033-1335064     Document Type: Article

References (41)

1. Parkin D. M., Bray F., Ferlay J. et al. Global Cancer Statistics, 2002. CA: A Cancer Journal for Clinicians: 2005; 55 74 108 (Pubitemid 40372904)
2. Karapetis C., Khambata-Ford S., Jonker D. et al. K-ras mutations and benefit from betuximab in bdvanced colorectal caner. New Engl J Med: 2008; 359 1757 1765
3. Au H. J., Karapetis C., Callaghan O. et al. Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: Overall and KRSA-specific results of the NCIC CTG and AGITG CO.17 trial. J Clin Oncol: 2009; 27 1822 1828
4. Andreis F., Rizzi A., Mosconi P. et al. Quality of life in colon cancer patients with skin side effects: preliminary results from a monocentric cross sectional study. Health Qual Life Outcomes: 2010; 8 40 47
5. Tol J., Koopman M., Cats A. Supplement to: chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. New Engl J Med 2009A 360 563 572
6. Zabora J., Brintzenhofeszoc K., Kurbow B. et al. The prevalence of psychological distress by cancer site. Psycho-Oncology: 2001; 10 19 28 (Pubitemid 32106774)
7. Merckaert I., Libert Y., Messin S. et al. Cancer patients' desire for psychological support: prevalance and implications for screening patients' psychological needs. Psycho-Oncology: 2010; 19 141 149
8. Romito F., Giuliani F., Cormio C. et al. Psychological effects of cetuximab-induced cutaneous rash in advanced colorectal cancer patients. Supportive Care Cancer: 2009; 18 329 334
9. Rehse B., Pukrop R. Effects of psychosocial interventions on quality of life in adult cancer patients: meta-analysis of 37 published controlled outcome studies. Patient Educ Counseling: 2003; 50 179 186 (Pubitemid 36627427)
10. World Health Organization WHOQOL. Measuring quality of life. Geneva World Health Organization: 1997
11. Velikova G., Awad N., Coles-Gay R. et al. The clinical value of quality of life assessments in oncology practice- a qualitative study of patient and physician views. Psycho-Oncology: 2008; 17 690 698
12. Gordon H., Guyatt M. D., Sander J. O. et al. Measuring quality of life in clinical trials. A taxonomy and review. Can Med Assoc J: 1989; 140 1441 1448
13. Tol J., Koopman M., Cats A. et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. New Engl J Med 2009B 360 563 572
14. Lacouture M. E., Mitchell E. P., Piperdi B. et al. Skin toxitiy evaluation protocol with Panitumumab (STEPP), a phase II, open-label, randomized trial evaluation the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colocrectal cancer. J Clin Oncol: 2010; 28 1351 1357
15. Härtl K., Engel J., Herschbach P. et al. Personality traits and psychological stress: quality of life over 2 years following breast cancer diagnosis and psychological impact factors. Psycho-Oncoloy: 2010; 19 160 169
16. Oken M. M., Creech R. H., Tormey D. C. et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol: 1982; 5 649 655 (Pubitemid 13149996)
17. Knight L., Mussell M., Brandl T. et al. Development and psychometric evaluation of the Basic Documentation for Psycho-Oncoloy (PO-Bado), a tool for standardized assessment of cancer patients. J Psychosom Res: 2005; 64 373 381 (Pubitemid 351417919)
18. Fahrenberg J., Myrtek M., Schumacher J. et al. Fragebogen zur Lebenszufriedenheit (FLZ). Handanweisung. Göttingen Hogrefe: 2001
19. Hautzinger M., Bailer M., Worall H. et al. Beck-Depressions-Inventar (BDI). Bern Hans Huber: 1995
20. Borkenau P., Ostendorf F. NEO-Fünf-Faktoren Inventar nach Costa und McCrae (NEO-FFI). Manual. Göttingen Hogrefe: 2005
21. Lohaus A., Schmitt G. M. Fragebogen zur Erhebung von Kontrollü berzeugungen zu Krankheit und Gesundheit (KKG). Göttingen Hogrefe: 1998
22. Muthny F. A. Freiburger Fragebogen zur Krankheitsverarbeitung. Göttingen Hogrefe: 1989
23. National Cancer Institute (NCI) Common toxicity criteria. Bethesda, Maryland (USA) Division of Cancer Treatment, National Cancer Institute: 1988
24. Schäfer T., Staudt A., Ring J. German instrument fort the assessment of quality of life in skin deseases (DIELH). Internal consistency, reliability, convergent and discriminant validity and responsiveness. Der Hautarzt: 2001; 52 624 628 (Pubitemid 32685557)
25. Fawzy I. F. Psychosocial interventions for patients with cancer: what works and what doesn't. Eur J Cancer: 1999; 35 1559 1564
26. Livneh H. Psychological adaption to cancer: the role of coping strategies. The J Rehabil: 2000; 66 43 51
27. Herschbach P. The well-being paradox in quality-of-life research. Psychother Psychosom Med Psychol: 2002; 52 141 150
28. Sprangers M. AG, Moinpur C. M., Moynihan T. J. et al. Assessing meaningful change in quality of life over time: A useŕs guide for clinicians. Mayo Clin Proc: 2002; 77 561 571 (Pubitemid 34587346)
29. Rapkin B. D., Schwartz C. E. Toward a theoretical model of quality-of-life appraisal: implications of findings from studies of response shift. Health Qual Life Outcomes: 2004; 2 14 18
30. Saif M. W., Longo W., Israel G. Correlation between rash and a positive drug response associated with cetuximab in a patient with advanced colorectal cancer. Clin Colorect Cancer: 2008; 7 144 148 (Pubitemid 351518777)
31. Gotlib V., Khaled S., Lapko I. et al. Skin rash secondary to cetuximab in patient with advances colorectal cancer and relation to response. Anticancer Drugs: 2006; 17 1227 1229 (Pubitemid 44673405)
32. Thompson A. GH, Sunol R. Expectations as determinants of patient satisfaction: concepts, theory and evidence. Int J Qual Health Care: 1995; 7 127 141
33. Carr A. J., Gibson B., Robinson P. G. Is quality of life determined by expectations or experience? Br Med J: 2001; 322 1240 1243 (Pubitemid 32453083)
34. Bandura A. Self-efficacy: Toward a unifying theory of behavioral change. Psychol Rev: 1977; 84 191 215
35. Allison P. J., Locker D., Feine J. S. Quality of life: A dynamic construct. Social Sci Med: 1997; 45 221 230 (Pubitemid 27270372)
36. Spencer S. M., Carver C. S., Price A. A. Psychological and social factors in adaptation. In J.C Holland. (Ed) Psychooncology. (pp 211-222) New York Oxford Press: 1998
37. Bech P. Quality of life measurements in major depression. Eur Psychiatry: 1996; 11 123 126 (Pubitemid 26191726)
38. Lazarus R. S., Folkman S. Stress, appraisal, and coping. New York Springer: 1984
39. Magnus K., Diener E., Fujita F. et al. Extraversion and neuroticism as predictors for objective life-events. A longitudinal analysis. J Personality Social Psychol: 1993; 65 1046 1053
40. Diener E., Suh E., Lucas R. E. et al. Subjective well-being: Three decades of progress. Psychol Bull: 1999; 125 276 302
41. Matthews G., Deary I. J. Personality traits. Cambridge, UK Cambridge University Press: 1998